Richard Kefford
Overview
Explore the profile of Richard Kefford including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
7833
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Khoo C, Gilchrist J, Williamson J, Paul M, Kefford R
Respirol Case Rep
. 2019 Jul;
7(7):e00459.
PMID: 31312456
A 70-year-old woman underwent adjuvant chemotherapy with dose-dense doxorubicin and cyclophosphamide for early breast cancer. After her fourth cycle of chemotherapy, she developed severe fatigue and cough with rapid-onset hypoxic...
12.
Long G, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandala M, et al.
J Clin Oncol
. 2019 Apr;
37(15):1356-1358.
PMID: 30939092
No abstract available.
13.
Schadendorf D, Hauschild A, Santinami M, Atkinson V, Mandala M, Chiarion-Sileni V, et al.
Lancet Oncol
. 2019 Apr;
20(5):701-710.
PMID: 30928620
Background: In the phase 3 COMBI-AD study, patients with resected, stage III melanoma with BRAF or BRAF mutations received adjuvant dabrafenib plus trametinib or placebo. The primary analysis showed that...
14.
Joseph R, Elassaiss-Schaap J, Kefford R, Hwu W, Wolchok J, Joshua A, et al.
Clin Cancer Res
. 2018 Dec;
24(23):6098.
PMID: 30510087
No abstract available.
15.
Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandala M, et al.
J Clin Oncol
. 2018 Oct;
36(35):3441-3449.
PMID: 30343620
Purpose: Dabrafenib plus trametinib improved relapse-free survival (RFS) versus placebo (hazard ratio [HR], 0.47; < .001) in patients with resected V600-mutant stage III melanoma (BRF115532; COMBI-AD; ClinicalTrials.gov identifier: NCT01682083). We...
16.
Helgadottir H, Ghiorzo P, van Doorn R, Puig S, Levin M, Kefford R, et al.
J Med Genet
. 2018 Oct;
57(5):316-321.
PMID: 30291219
Background: Inherited mutation is a strong risk factor for cutaneous melanoma. Moreover, carriers have been found to have poor melanoma-specific survival. In this study, responses to novel immunotherapy agents in...
17.
Irvine M, Stewart A, Pedersen B, Boyd S, Kefford R, Rizos H
Oncogenesis
. 2018 Sep;
7(9):72.
PMID: 30237495
Nearly all patients with BRAF-mutant melanoma will progress on BRAF inhibitor monotherapy and combination BRAF/MEK inhibitor therapy within the first year of therapy. In the vast majority of progressing melanomas,...
18.
Joseph R, Elassaiss-Schaap J, Kefford R, Hwu W, Wolchok J, Joshua A, et al.
Clin Cancer Res
. 2018 Apr;
24(20):4960-4967.
PMID: 29685882
The purpose of this study was to assess the association of baseline tumor size (BTS) with other baseline clinical factors and outcomes in pembrolizumab-treated patients with advanced melanoma in KEYNOTE-001...
19.
Robert C, Ribas A, Hamid O, Daud A, Wolchok J, Joshua A, et al.
J Clin Oncol
. 2017 Dec;
36(17):1668-1674.
PMID: 29283791
Purpose Pembrolizumab provides durable antitumor activity in metastatic melanoma, including complete response (CR) in about 15% of patients. Data are limited on potential predictors of CR and patient disposition after...
20.
Long G, Eroglu Z, Infante J, Patel S, Daud A, Johnson D, et al.
J Clin Oncol
. 2017 Oct;
36(7):667-673.
PMID: 28991513
Purpose To report 5-year landmark analysis efficacy and safety outcomes in patients with BRAF V600-mutant metastatic melanoma (MM) who received BRAF inhibitor dabrafenib (D) and MEK inhibitor trametinib (T) combination...